Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious ... Adma Biologics Inc. is a biotechnology company that focuses on the development, manufacture, and commercialization of specialty plasma-derived biologics for the treatment and prevention of infectious diseases. At the core of its operations is the processing of human plasma to produce immunoglobulin products aimed at addressing immune deficiencies and other complex health conditions. The company's prominent products include Bivigam, an intravenous immunoglobulin used for the treatment of primary humoral immunodeficiency, and Asceniv, another intravenous immunoglobulin specifically tailored with hyperimmune antibodies. Adma Biologics serves critical roles within the healthcare sector, particularly in treating patients with immune system disorders, thus supporting a niche yet vital component of the pharmaceutical supply chain. Their products are crucial in meeting the demands of patients who require regular immune system support, distilling unique proteins and antibodies from donated plasma to help bolster patient health. With headquarters in Ramsey, New Jersey, and Boca Raton, Florida, the company plays a significant role in the advancements of plasma-derived therapeutics, catering to both domestic and international needs.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by ADMA Biologics

We reviewed ADMA Biologics's website and available disclosure materials for the 2023 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review ADMA Biologics's data?

Create a free Tracenable account to signal interest in having our team review data for ADMA Biologics.

Legal Center Contact Us